Search results
Showing 226 to 240 of 720 results for pain management
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Joint distraction for knee osteoarthritis without alignment correction (HTG381)
Evidence-based recommendations on joint distraction for knee osteoarthritis without alignment correction. This involves fixing a metal frame around the knee to take weight off the joint and encourage the cartilage to repair itself.
View recommendations for HTG381Show all sections
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)
NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Early value assessment (EVA) guidance on digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis.
Endometriosis: diagnosis and management - surgical management - pain management post-surgery
Discontinued Reference number: GID-NG10385
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.
View quality statements for QS79Show all sections
Sections for QS79
- Quality statements
- Quality statement 1: Diagnosis of idiopathic pulmonary fibrosis
- Quality statement 2: Access to a specialist nurse
- Quality statement 3: Assessment for oxygen therapy
- Quality statement 4: Pulmonary rehabilitation
- Quality statement 5: Palliative care
- Update information
- About this quality standard
This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.
from the medicine. The most common mild side effects are headache, abdominal pain, nausea, diarrhoea, vomiting, and increased gas....
Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)
Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.
View recommendations for HTG560Show all sections
Powered microdebrider turbinoplasty for inferior turbinate hypertrophy (HTG347)
Evidence-based recommendations on powered microdebrider turbinoplasty for inferior turbinate hypertrophy. This involves cutting away some of the swollen membrane covering the turbinates.
View recommendations for HTG347Show all sections
Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)
Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older.
Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.